About Us Contact Us Disclaimer Sitemap
  New Old
left «« +1 «« -1 right
  Equity Analysis
Gainers & Losers
Out & Under Performers
Only Buyers & Sellers
Advances & Declines
New Highs & Lows
5 Day's Up & Down
Historical Returns
  News Analysis
Corporate Action
  Corporate Info
  Other Market
Company Profile  
Cipla Ltd.
BSE Code 500087
ISIN Demat INE059A01026
Book Value(Rs.) 222.96
Dividend Yield % 0.52
Market Cap(Rs. in millions) 616103.75
P/E 27.57
EPS 27.71
Face Value(Rs.) 2  

Chemical, Industrial & Pharmaceutical Laboratories, now known as Cipla, was incorporated 1935.Khwaja Abdul Hamied, the founder of Cipla gave the company all his patent and proprietary formulas for several drugs and medicines, without charging any royalty. On August 17, 1935, Cipla was registered as a public limited company with an authorised capital of Rs 6 lakhs.Cipla is a leading global pharmaceutical company, dedicated to high-quality, branded and generic medicines.

Business of the company:

The company focuses on development of new formulations and has a wide range of pharmaceutical products. It offers prescription drugs, bulk drugs, animal products and pesticides. It also offers a wide range of food and beverages, baked foods, oral hygiene products, detergents, room fresheners and personal care products.

Almost 55% of its overall income from its operations come from outside India. It has 5,500 registered products in various countries.Cipla offers drugs used for treatment of cancer, Alzheimer's, arthritis, Parkinson’s, cardiovascular diesases and many more. It also offers drugs that prevents transmission of AIDS from mother to child.The company provides consulting services on preparation of products and materials, conducts plant evaluation and supplies plant equipments.

Cipla has set up two institutes namely Dr K.A Hamied Institute and Cipla Cancer Palliative Care & Training Centre.It has a presence across 170 countries with manufacturing units approved by regulatory authorities like USFDA, WHO-Canada and MHRA-UK, among others.

Cipla was first company outside US and Europe to launch CFC-free inhalers. In 2007 Cipla launched oral emergency contraceptive pill under the brand name I-Pill. Cipla also launched a breakthrough screening technology in India called the ‘No Touch Breast Scan (NTBS); ' the first-ever painless, non-invasive and radiation-free breast scanning technique for detecting breast cancer at an early stage.

In 2009, Cipla launched generic versions of anti-flu drugs oseltamivir and zanamivir in the local market to treat the H1N1 influenza, spreading across the globe and in India. In 2010, Piramal Healthcare Limited announced the signing of a definitive agreement with Cipla Limited for purchase of all intellectual property rights in India related to 'i-pill' for an aggregate consideration of Rs 95 crore.


The company won the Forbes Asia's “Best Under A Billion” List from Forbes Magazine.

Cipla also won the Most Profitable Company overall among those “Under a Billion in the Region’s Top 200 Small and Mid Size companies” from Forbes Magazine.


1935-Dr K A Hamied sets up 'The Chemical, Industrial and Pharmaceutical Laboratories Ltd.' in a rented bungalow, at Bombay Central. 1941-As the Second World War cuts off drug supplies, the company starts producing fine chemicals, dedicating all its facilities for the war effort. 1952- Sets up first research division for attaining self-sufficiency in technological development. 1960- Starts operations at second plant at Vikhroli, Mumbai, producing fine chemicals with special emphasis on natural products. 1968- Cipla manufactures ampicillin for the first time in the country. 1972-Starts Agricultural Research Division at Bangalore, for scientific cultivation of medicinal plants. 1976-Cipla launches medicinal aerosols for asthma. 1980-Wins Chemexcil Award for Excellence for exports. 1982-Fourth factory begins operations at Patalganga, Maharashtra. 1984-Develops anti-cancer drugs, vinblastine and vincristine in collaboration with the National Chemical Laboratory, Pune.

Wins Sir P C Ray Award for developing inhouse technology for indigenous manufacture of a number of basic drugs. 1985-US FDA approves Cipla's bulk drug manufacturing facilities. 1988-Cipla wins National Award for Successful Commercialisation of Publicly Funded R&D. 1991-Lauches etoposide, a breakthrough in cancer chemotherapy, in association with Indian Institute of Chemical Technology.

The company pioneers the manufacture of the antiretroviral drug, zidovudine, in technological collaboration with Indian Institute of Chemical Technology, Hyderabad. 1994-Cipla's fifth factory begins commercial production at Kurkumbh, Maharashtra. 1997-Launches transparent Rotahaler, the world's first such dry powder inhaler device now patented by Cipla in India and abroad. The palliative cancer care centre set up by the Cipla Foundation, begins offering free services at Warje, near Pune.

 1998- Launches lamivudine, becoming one of the few companies in the world to offer all three component drugs of retroviral combination therapy (zidovudine and stavudine already launched). 1999-Launches Nevirapine, antiretroviral drug, used to prevent the transmission of AIDS from mother to child. 2000-Cipla became the first company, outside the USA and Europe to launch CFC-free inhalers – ten years before the deadline to phase out use of CFC in medicinal products. 2002-Four state-of-the-art manufacturing facilities set up in Goa in a record time of less than twelve months. 2003-Launches TIOVA (Tiotropium bromide), a novel inhaled, long-acting anticholinergic bronchodilator that is employed as a once-daily maintenance treatment for patients with chronic obstructive pulmonary disease (COPD).Commissioned second phase of manufacturing operations at Goa. 2005-Sest-up state-of-the-art facility for manufacture of formulations at Baddi, Himachal Pradesh.

2007-Sets-up state-of-the-art facility for manufacture of formulations at Sikkim. 2010-Sets up state-of-the-art facility for manufacture of formulations at Indore.

2014-MMV announces collaborations with Cipla and Strides. -Cipla announces a distribution agreement with SII for affordable paediatric vaccines in Europe. -Cipla Medpro announces collaboration with word's largest generic pharmaceutical company.

  • Cipla strengthens its presence in Kenya. - MPP Adds New Sub-Licensing Agreements to Improve Access to Novel ARVs. - Cipla enters into a licensing agreement with Gilead. - Cipla, S&D Pharma collaborate to enter Czech Republic and Slovakia.
  • Launch of Serroflo (Salmeterol/ Fluticasone MDI) in Germany and Sweden. - Cipla, BioQuiddity announce EU Commercial Partnership for OneDose-ReadyfusOR. - Sub-Licences agreement with Medicines Patent Pool for Dolutegravir.
  • Cipla to expand global footprint, plans investment in its UK subsidiary.
  • Cipla collaborates with Hetero to launch its second biosimilar drug.
  • Cipla invests in Chase Pharmaceuticals to support Alzheimer’s disease drug development. - MSD and Cipla announce India-specific Strategic Partnership to Co-market MSD’s raltegravir.                             

2015- Cipla Announces Launch of Hepcvir-L for ChronicHepatitis C Genotype 1 Patients. - Cipla launches novel “5 in 1” anti-ageing skin care product Cutisera developed by Stempeutics.

  • Cipla ready to launch low-dose Efavirenz 400 mg. - Cipla Strengthens its Focus on Biotech.
  • Cipla Medpro (Pty) Ltd. partners with Serum Institute India (SII) to Provide Vaccines in South Africa.
  • Cipla to acquire 100% of generic businesses in US for $550M. - Cipla announces a new respiratory inhaler Synchrobreathe(SB).
  • Cipla announces investment led by Fidelity Growth Partners India into Consumer Healthcare business.
  • Stempeutics receives Japan process patent for its novel stem cell drug ‘Stempeucel’.
  • Cipla Announces US FDA Approval for LPV/r Oral Pellets for Treatment of AIDS in Infants.
  • Stempeutics receives ODD in the European Union for its novel stem cell drug “Stempeucel”.
  • Cipla announces distribution agreement with SII for flu vaccine ‘Nasovac-S’ for India.
  • Stempeutics gets stem cell patent in China for its novel stem cell drug “Stempeucel”.
  • Cipla announces the launch of generic drug Sofosbuvir in India under the brand name ‘Hepcvir’. Stempeutics receives ATMP classification from EMA for its novel stem cell drug “Stempeucel”. - Stempeutics receives US process patent for its novel stem cell drug “Stempeucel”.
  • Cipla wins $ 188.95 million of Global Fund ARV Tender.
  • Cipla’s U.K. subsidiary enters into a JV with Cooper Pharma and PHI.

2016- Cipla’s Flagship Product Sereflo Receives Final Approval from UK MHRA.

  • Cipla Receives Final Approval for Generic Tricor Tablets.
  • Cipla receives final approval for generic Baraclude tablets.
  • Cipla EU divests stake in Chase Pharmaceuticals to Allergan.
  • Cipla Receives EIR from the US FDA for its Indore facility.
  • Cipla Receives Final Approval for Generic Enablex Tablets.
  • Cipla Receives Final Approval for Generic Wellbutrin XL Tablets.
  • Cipla joins global movement to eliminate viral hepatitis by 2030.
  • Cipla to launch South Africa’s first Biotech manufacturing facility.
  • Nacimbio launches complex programme for antiretroviral drugs production.
  • DCGI gives limited approval to market first allogeneic cell therapy product in India.
  • Cipla completes acquisition of generic businesses in US.
  • Global pharmaceutical industry calls on governments to work with them to beat the rising threat of drug resistance.
  • Declaration by the Pharmaceutical, Biotechnology and Diagnostics Industries on Combating Antimicrobial Resistance.
  • The Medicines Patent Pool Signs First Sub-licences for Hepatitis C Medicine Daclatasvir.
  • BioQ Pharma and Cipla enter into an Agreement to Commercialize BioQ’s Ropivacaine Infusion System in India.                           

2017- Cipla launches Rectal Artesunate Suppositories for severe malaria in young children.

  • Cipla Announces Collaboration with MEDRx.- Cipla Receives Final Approval for Generic Epzicom Tablets.
  • Cipla agrees to divest its animal health business in SA and Sub-Saharan Africa.
  • Cipla launches Hepatitis B vaccine in India.'
Terms & Conditions Copyright ©ATLAS All rights reserved. Designed || Developed & Content Powered By Accord Fintech Pvt.Ltd.

Important Links : SEBI | NSE | BSE | RBI | CDSL | NSDL | Investor Grievance| Policy
SEBI REG. NO. NSE : CASH INZ000166836; FO INZ000166836| BSE : CASH INZ000166836; FO INZ000166836
PMS : INP000000530 | AMFI : ARN0770 | CDSL : IN-DP-CDSL-465-2008